Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast cancer.

Trial Details

NCT ID
NCT07220135
Phase
PHASE2
Sponsor
University of Kansas Medical Center
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Carboplatin
  • Docetaxel
  • Trastuzumab (or biosimilar)
  • Pertuzumab (or biosimilar)
Locations (sample)
  • Fairway, Kansas, United States|39.02223,-94.6319
  • Kansas City, Kansas, United States|39.11417,-94.62746
  • Overland Park, Kansas, United States|38.98223,-94.67079
  • Overland Park, Kansas, United States|38.98223,-94.67079
  • Westwood, Kansas, United States|39.04056,-94.6169

Key Eligibility Criteria

  • Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written in…
  • 18 years of age or older
  • Histologically confirmed cT2-T3 N0-N2, cT1 N1-N2, or cTX N1-N2 HER2 positive breast cancer (The invasive tumor must be HER2-positive based on the c…
  • No previous ipsilateral breast surgery for the current breast cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →